Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 1986-1993

  Yan, Y ^a   Li, X ^b   Blanchard, A ^c   Bramwell, V H C ^d   Pritchard, K I ^e   Tu, D ^b   Shepherd, L ^b   Myal, Y ^c   Penner, C ^c   Watson, P H ^f   Leygue, E ^a   Murphy, L C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f British Columbia Cancer Victoria Center   (Canada)

Author keywords

Early breast cancer; Estrogen receptor alpha; Estrogen receptor beta; NCIC CTG MA12; Steroid receptor rna activator protein; Tamoxifen sensitivity

Indexed keywords

ESTROGEN RECEPTOR BETA 1; PLACEBO; STEROID RECEPTOR RNA ACTIVATOR PROTEIN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFECT; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL TIME;

EARLY BREAST CANCER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NCIC-CTG-MA12; STEROID RECEPTOR RNA ACTIVATOR PROTEIN; TAMOXIFEN SENSITIVITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARRIER PROTEINS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; PLACEBOS; PREMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879474652     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt132     Document Type: Article

References (36)

1. Murphy LC, Leygue E. The role of estrogen receptor-beta in breast cancer. Semin Reprod Med 2012; 30: 5-13.
2. Leung YK, Lee MT, Lam HM, et al. Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids 2012; 77: 727-737.
3. Stewart J, King R, Hayward J, et al. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat 1982; 2: 243-250.
4. von Maillot K, Gentsch HH, Gunselmann W. Steroid receptors and response to endocrine treatment and chemotherapy of advanced breast cancer. J Cancer Res Clin Oncol 1980; 98: 301-313.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
7. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
8. Murphy L, Watson P. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine Related Cancer 2006; 13: 327-334.
9. Murphy L, Cherlet T, Lewis A, et al. New insights into estogen receptor function in human breast cancer. Ann Med 2003; 35: 614-631.
10. Skliris G, Leygue E, Curtis-Snell L, et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006; 95: 616-626.
11. Jensen E, Cheng G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001; 98: 15197-15202.
12. O'Neill P, Davies M, Shaaban A, et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer. 2004; 91: 1694-1702.
13. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727-3734.
14. Gruvberger-Saal S, Bendahl P, Saal L, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13: 1987-1994.
15. Chooniedass-Kothari S, Vincett D, Yan Y, et al. The protein encoded by the functional steroid receptor RNA activator is a new modulator of ER alpha transcriptional activity. FEBS Lett 2010; 584: 1174-1180.
16. Chooniedass-Kothari S, Hamedani MK, Auge C, et al. The steroid receptor RNA activator protein is recruited to promoter regions and acts as a transcriptional repressor. FEBS Lett 2010; 584: 2218-2224.
17. Borth N, Massier J, Franke C, et al. Chlamydial protease CT441 interacts with SRAP1 co-activator of estrogen receptor alpha and partially alleviates its coactivation activity. J Steroid Biochem Mol Biol 2010; 119: 89-95.
18. Yan Y, Skliris GP, Penner C, et al. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/ younger breast cancer patients. Breast Cancer Res 2009; 11: R67.
19. Bramwell VH, Pritchard KI, Tu D, et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann Oncol 2010; 21: 283-290.
20. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012; 18: 4465-4472.
21. Leav I, Lau K-M, Adams J, et al. Comparative studies of the estrogen receptor b and a and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
22. Weitsman G, Skliris G, Ung K, et al. Assessment of multiple different oestrogen receptor b antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 2006; 100: 23-31.
23. Skliris GP, Rowan BG, Al-Dhaheri M, et al. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat 2009; 118: 443-453.
24. Skliris G, Leygue E, Watson P, et al. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 2008; 109: 1-10.
25. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-622.
26. Pastore MB, Jobe SO, Ramadoss J, et al. Estrogen receptor-alpha and estrogen receptor-beta in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow. Semin Reprod Med 2012; 30: 46-61.
27. Simoncini T. Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging. Climacteric 2009; 12(Suppl 1): 6-11.
28. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007; 28: 521-574.
29. Muschenheim F, Furst J, Bates H. Increased incidence of positive tests for estrogen binding in mammary carcinoma specimens transported in liquid nitrogen. Am J Clin Pathol. 1978; 70: 780-782.
30. Clarke R, Leonessa F, Welch J, et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 2001; 53: 25-71.
31. Murphy L, Peng B, Lewis A, et al. Inducible upregulation of oestrogen receptorbeta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol. 2005; 34: 553-566.
32. Cooper C, Guo J, Yan Y, et al. Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res 2009; 37: 4518-4531.
33. Horwitz KB, McGuire WL, Pearson OH, et al. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726-727.
34. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol 1979; 117: 95-110.
35. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
36. Novelli F, Milella M, Melucci E, et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008; 10: R74.